Iron Gate Global Advisors’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Iron Gate Global Advisors’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-539	Closed	-$52K	–	230
2018 Q3	$52K	Sell	539 -92	-15%	-$9.74K	0.03%	115
2018 Q2	$53K	Buy	+631	New	+$46.2K	0.04%	88

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Iron Gate Global Advisors's ICPT Position: Q4 2018 in Review

Iron Gate Global Advisors sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2018, closing a stake of 539 shares — an estimated $52K sold.

Iron Gate Global Advisors first reported a position in ICPT in Q2 2018 and held it in 2 quarters. The position peaked at $53K in Q2 2018. 191 funds tracked by Wall St. Rank hold ICPT as of Q4 2018.

Iron Gate Global Advisors reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
Iron Gate Global Advisors sold 539 Intercept Pharmaceuticals, Inc. shares in Q4 2018, an estimated $52K.
Iron Gate Global Advisors first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2018 and held it in 2 quarters.
Iron Gate Global Advisors's Intercept Pharmaceuticals, Inc. position peaked at $53K in Q2 2018.
191 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2018.

Based on Iron Gate Global Advisors's 13F filing for Q4 2018, filed 19 Feb 2019.